Phase 3 trial: Trastuzumab Deruxtecan, HER2-directed ADC with topoisomerase I inhibition.

This Phase 3 randomized, open-label trial by Daiichi Sankyo compares T‑DXd with bevacizumab combination therapy versus bevacizumab monotherapy as first-line maintenance for patients with stage 3/4 high-grade HER2-expressing ovarian cancer. The study evaluates a novel ADC-VEGF inhibition approach in this eligible population.